Methods of identifying drugs with selective effects against canc

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

435 32, C12Q 168

Patent

active

056459882

ABSTRACT:
The present invention involves a method of identifying drugs which selectively inhibit the growth of particular cancer cells, which method comprises: (a) contacting with the drug at least two cancer cells derived from the same type of biological material, wherein the cancer cells differ as to the presence of a particular DNA sequence, (b) measuring the effect of the drug on the growth of the cancer cells, and (c) determining whether there is a correlation between the effect of the drug on the cancer cells and the presence or absence of the DNA sequence in the cancer cells. The present invention further involves the use of such drugs.

REFERENCES:
patent: 4357352 (1982-11-01), Swallow
patent: 4885238 (1989-12-01), Reddel et al.
patent: 5034544 (1991-07-01), Elliott
patent: 5248671 (1993-09-01), Smith
Bai et al., "Halichondrin B and Homohalichondrin B, Marine Natural Products Binding in the Vinca Domain of Tubulin", J. Biolog. Chem., 266, 15882-15889 (1991).
Barbacid, "ras Genes", Ann. Rev. Biochem., 56, 779-837 (1987).
Bos, "ras Oncogenes in Human Cancer: A Review", Cancer Research, 49, 4682-4689, (1989).
Monks et al., "Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines", Journal of the National Cancer Institute, 83:11, 757-766 (1991).
Paull et al., "Display and Analysis of Patterns of Differential Activity of Drugs Against Human Tumor Cell Lines: Development of Mean Graph and Compare Algorithm", Journal of the National Cancer Institute, 81:14, 1088-1092 (1989).
Paull et al., "Identification of Novel Antimitotic Agents Acting at the Tubulin Level by Computer-assisted Evaluation of Differential Cytotoxicity Data", Cancer Research, 52, 3892-3900 (1992).
Perkins et al., "Principles of Molecular Cell Biology of Cancer: Oncogenes", In: Cancer: Principles & Practice of Oncology, 4th Ed., DeVita, Jr., et al., eds., 35-57 (PA: J.B. Lippincott Co., 1993).
Siegel, "Measures of Correlation and Their Tests of Significance", Nonparametric Statistics for the Behavioral Sciences, 195-213 (NY: McGraw-Hill Book Co., 1956).
Skehan et al., "New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening", Journal of the National Cancer Institute, 82:13, 1107-1112 (1990).
Snedecor et al., "Correlation", In: Statistical Methods, 7th Ed., 175-193 (Ames, IA: The Iowa State University Press, 1980).
Weinstein et al., "Neural Computing in Cancer Drug Development: Predicting Mechanism of Action", Science, 258, 447-451 (1992).
Wu et al., "Multidrug-resistant Phenotype of Disease-oriented Panels of Human Tumor Cell Lines Used for Anticancer Drug Screening", Cancer Research, 52, 3029-3034 (1992).
Bos, Cancer Research, vol. 49, 1989, pp. 4682-4689.
Alley et al., Cancer Research, vol. 48, 1988, pp. 589-601.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Methods of identifying drugs with selective effects against canc does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of identifying drugs with selective effects against canc, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of identifying drugs with selective effects against canc will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2408199

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.